Galapagos Genomics NV And Cellzome AG In Kinase Drug Discovery Collaboration

MECHELEN, BELGIUM--(MARKET WIRE)--Jul 19, 2006 -- Mechelen, Belgium and Boston, U.S.; 19 July 2006 - Galapagos NV (Euronext & LSE: GLPG), an integrated drug discovery company, and Cellzome Inc. have announced that they are collaborating in kinase drug discovery. Under the terms of the agreement, Galapagos' service division BioFocus DPI gives Cellzome access to its SoftFocus® kinase libraries and provides biological screening and chemistry expertise to find inhibitors of Cellzome's kinase targets. In this service contract, BioFocus DPI receives an upfront payment for the library access as well as research fees.